In other words, the price has increased by $0.0000 from its previous closing price. On the day, 1319842 shares were traded.
Ratios:
Our goal is to gain a better understanding of CYTH by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.80 and its Current Ratio is at 0.83.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 01 ’23 when Rafael Holdings, Inc. bought 4,000,000 shares for $1.25 per share. The transaction valued at 5,000,000 led to the insider holds 6,514,970 shares of the business.
FINE N SCOTT bought 299,402 shares of CYTH for $212,575 on Apr 20 ’23. The Chief Executive Officer now owns 444,402 shares after completing the transaction at $0.71 per share. On Apr 20 ’23, another insider, Ostronic Francis Patrick, who serves as the Director of the company, bought 59,881 shares for $0.71 each. As a result, the insider paid 42,516 and bolstered with 222,371 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTH now has a Market Capitalization of 47.75M and an Enterprise Value of 45.99M. For the stock, the TTM Price-to-Sale (P/S) ratio is 38.83. Its current Enterprise Value per Revenue stands at 48.32 whereas that against EBITDA is -2.38.
Stock Price History:
Over the past 52 weeks, CYTH has reached a high of $2.57, while it has fallen to a 52-week low of $0.67. The 50-Day Moving Average of the stock is 1.6904, while the 200-Day Moving Average is calculated to be 1.5137.
Shares Statistics:
The stock has traded on average 96.77K shares per day over the past 3-months and 174.8k shares per day over the last 10 days, according to various share statistics. A total of 22.77M shares are outstanding, with a floating share count of 10.02M. Insiders hold about 56.00% of the company’s shares, while institutions hold 9.71% stake in the company. Shares short for CYTH as of Feb 29, 2024 were 63.34k with a Short Ratio of 0.65, compared to 158.85k on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.22% and a Short% of Float of 0.26%.
Earnings Estimates
Its stock is currently analyzed by 0 different market analysts. On average, analysts expect EPS of $0 for the current quarter, with a high estimate of $0 and a low estimate of $0, while EPS last year was -$0.5. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0. EPS for the following year is $0, with 0 analysts recommending between $0 and $0.
Revenue Estimates
A total of 1 analysts have provided revenue estimates for CYTH’s current fiscal year. The highest revenue estimate was $1.65M, while the lowest revenue estimate was $1.65M, resulting in an average revenue estimate of $1.65M. In the same quarter a year ago, actual revenue was $1.38M, up 19.90% from the average estimate. Based on 1 analysts’ estimates, the company’s revenue will be $3.3M in the next fiscal year. The high estimate is $3.3M and the low estimate is $3.3M. The average revenue growth estimate for next year is up 100.00% from the average revenue estimate for this year.
